(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes.
In a phase III trial…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/119048
Author :
Publish date : 2025-12-16 19:06:00
Copyright for syndicated content belongs to the linked Source.
